Advertisement
UK markets closed

  • FTSE 100

    8,433.76
    +52.41 (+0.63%)
     

  • FTSE 250

    20,645.38
    +114.08 (+0.56%)
     

  • AIM

    789.87
    +6.17 (+0.79%)
     

  • GBP/EUR

    1.1622
    +0.0011 (+0.09%)
     

  • GBP/USD

    1.2525
    +0.0001 (+0.01%)
     

  • Bitcoin GBP

    48,555.55
    -1,647.73 (-3.28%)
     

  • CMC Crypto 200

    1,260.36
    -97.65 (-7.19%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     

  • DAX

    18,772.85
    +86.25 (+0.46%)
     

  • CAC 40

    8,219.14
    +31.49 (+0.38%)
     
MONEY:

Best savings accounts that offer above inflation rates

How to earn the most interest on your savings

UK cost agency rebuffs Sanofi cholesterol drug but backs Amgen's

Reuters - UK Focus

LONDON, Feb 8 (Reuters) - Britain's cost watchdog has recommended that patients with high cholesterol should not get Sanofi (NasdaqGM: GCVRZ - news) and Regeneron's new cholesterol-lowering injection Praluent, although Amgen (Xetra: 867900 - news) 's similar drug Repatha will be available.

The National Institute for Health and Care Excellence (NICE (LSE: 0FEW.L - news) ) cost watchdog said in draft guidance on Monday that Praluent's benefits were uncertain and it was likely to overshoot standard cost-effectiveness thresholds.

NICE, which decides if drugs should be used on the state health service, had initially reached a similar decision for Amgen's product in November.

But in a change of heart on Friday it said Repatha could be an option for some patients, provided it was supplied at an agreed - but undisclosed - price discount.

Both Praluent and Repatha belong to a potent new class of drugs known as PCSK9 inhibitors that have proved highly effective at lowering "bad" LDL cholesterol. (Reporting by Ben Hirschler, editing by David Evans)